Inhibikase (IKT) director files Form 3/A disclosing 765,895 shares from merger

Rhea-AI Filing Summary

Inhibikase Therapeutics director Aurentz Vincent reported beneficial ownership of 765,895 shares of common stock in an amended Form 3/A. These shares were issued as merger consideration in connection with the acquisition of CorHepta Pharmaceuticals completed on 02/21/2025 and were added to an earlier Form 3 filed 02/25/2025.

Of the 765,895 shares, 127,649 vested on the closing date, 382,947 will vest on the first anniversary of the closing date, and 255,299 are contingent: 25% of that tranche vests upon achievement of a specified milestone and 75% vests on the first anniversary, subject to continued service; if the milestone is not achieved by the first anniversary, all 255,299 shares are forfeited.

Positive

• Shares issued as merger consideration demonstrate alignment of the reporting person with the combined company
• 127,649 shares vested on the closing date, providing immediate alignment and value realization
• 382,947 shares scheduled to vest on first anniversary, concentrating near-term, time-based alignment

Negative

• 255,299 shares are milestone-contingent and subject to forfeiture if the milestone is not achieved by the first anniversary
• Amendment was required to include omitted shares, indicating an earlier disclosure omission

Insights

Financial Analyst

TL;DR: Director received a material equity grant tied to a Feb 21, 2025 acquisition; most shares vest within one year.

The filing documents a non-cash merger consideration issuance of 765,895 shares to a reporting director following the CorHepta acquisition. Immediate economic alignment is shown by 127,649 shares vested at closing and a further 382,947 scheduled to vest on the one-year anniversary, concentrating near-term dilution timing. The remaining 255,299 shares are milestone-contingent with forfeiture risk, which limits guaranteed dilution. This is a routine executive/director post-acquisition equity allocation rather than operational financial disclosure.

Corporate Governance Expert

TL;DR: Amendment corrects an omission; vesting terms include service and milestone conditions with potential forfeiture.

The amended Form 3 clarifies previously omitted shares, reflecting a corrective disclosure practice. Vesting structure mixes immediate vesting, time-based vesting, and milestone-contingent vesting, aligning incentives to retention and achievement of a stated milestone. The amendment itself signals a filing oversight that was corrected; the substance shows standard post-merger equity treatment for a sellers' representative now serving as a director.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aurentz Vincent

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/21/2025

3. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	765,895(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.

2. Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 127,649 shares vested on the Closing Date, 382,947 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 255,299 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 255,299 shares shall be forfeited.

	/s/ Mark Iwicki, attorney-in-fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aurentz Vincent report on the Form 3/A for IKT?

The Form 3/A reports beneficial ownership of 765,895 shares of Inhibikase Therapeutics common stock issued as merger consideration related to the CorHepta acquisition.

When were these shares issued and why?

The shares were issued in connection with the acquisition of CorHepta Pharmaceuticals, which closed on 02/21/2025.

How do the shares vest according to the filing?

The filing states 127,649 shares vested on the closing date, 382,947 shares vest on the first anniversary, and 255,299 shares are milestone-contingent (25% on milestone, 75% on first anniversary; forfeited if milestone unmet by that date).

Was this the original Form 3 filing?

No. The Form 3/A amends the original Form 3 filed 02/25/2025 to include shares that were inadvertently omitted.

Does the filing indicate any derivatives or options?

No. Table II for derivative securities shows no entries; the reported holdings are non-derivative common stock.